Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011043 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
A Phase 1 study of Systemic Lupus Erythematosus, sponsored by Climb Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 18
- Study locations
NCT07011043 is a Phase 1 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by Climb Bio. The registered enrollment target is 30 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 4 states.
The verdict
NCT07011043, a Phase 1 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by Climb Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 18
- Study locations
Study Summary
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Conditions Studied
Interventions
- DRUG Budoprutug
Study Locations (18)
Other
- Climb Bio Investigative Site# 359101 - Plovdiv
- Climb Bio Investigative Site# 359102 - Sofia
- Climb Bio Investigative Site #995102 - Tbilisi
- Climb Bio Investigative Site #995101 - Tbilisi
- Climb Bio Investigative Site #100103 - Caguas
- Climb Bio Investigative Site# 400101 - Cluj-Napoca
- Climb Bio Investigative Site# 340102 - A Coruña
- Climb Bio Investigative Site #380102 - Ivano-Frankivsk
- Climb Bio Investigative Site #380103 - Kyiv
- Climb Bio Investigative Site #380106 - Kyiv
- Climb Bio Investigative Site #380101 - Ternopil
- Climb Bio Investigative Site #380104 - Vinnytsia
- Climb Bio Investigative Site #380105 - Vinnytsia
Texas
- Climb Bio Investigative Site #100104 - Allen
- Climb Bio Investigative Site #100101 - San Antonio
Thessaloniki
- Climb Bio Investigative Site# 300102 - Exochi
- Climb Bio Investigative Site# 300103 - Thessaloniki
Barcelona
- Climb Bio Investigative Site# 340101 - Sabadell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011043
The ClinicalTrials.gov registry entry for NCT07011043 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (92% lower). The listed sponsor is Climb Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Budoprutug is the first listed.
NCT07011043 reports 18 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, Thessaloniki.
Frequently Asked Questions
What is clinical trial NCT07011043 about?
NCT07011043 is a clinical study titled "A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)". The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
What is the current status of trial NCT07011043?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-07-10. Estimated completion is 2027-04.
What conditions does trial NCT07011043 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT07011043?
The interventions under investigation include: Budoprutug (DRUG).
Who is sponsoring clinical trial NCT07011043?
This trial is sponsored by Climb Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011043 being conducted?
This trial has 18 study locations across Texas, Thessaloniki, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.